MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/s2666-7568(22)00002-2

Медицинская библиотека · The lancet. Healthy longevity · 2022

Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study.

Falandry Claire, Pommeret Fanny, Gladieff Laurence, Tinquaut Fabien, Lorusso Domenica, Mouret-Reynier Marie-Ange, D'Hondt Véronique, Mollon-Grange Delphine, Floquet Anne, Abadie-Lacourtoisie Sophie, Brachet Pierre-Emmanuel, Stefani Laetitia, Rousseau Frédérique, Frenel Jean-Sébastien, Del Piano Francesco, Komulainen Marja, Warkus Thomas, Trédan Olivier, Pujade-Lauraine Eric, Freyer Gilles

Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Older patients with ovarian cancer represent a heterogeneous population. The French National Group of Investigators for the Study of Ovarian and Breast Cancer developed the geriatric vulnerability score (GVS) to identify geriatric parameters predictive of poor outcomes. A prospective validation of the GVS was needed.

METHODS

The EWOC-1 study (NCT02001272) was an international, open-label, phase 2, three-arm trial designed according to a two-step process. Patients aged 70 years or older with newly diagnosed stage III or IV ovarian cancer were identified and the GVS determined. Those with a GVS of 3 or greater were randomly assigned to the EWOC-1 trial, stratified by country and surgical outcome, to receive three different carboplatin with or without paclitaxel regimens; those not included in the EWOC-1 trial were followed up in the EWOC-1 registry. External validation of the GVS was a secondary endpoint of the trial. Three validation cohorts were identified: the total population (validation cohort 1 [V1], n=447), the registry-only population (validation cohort 2 [V2], n=327), and the carboplatin-paclitaxel-treated population (validation cohort 3 [V3], n=320).

FINDINGS: From Dec 11, 2013, to Nov 16, 2018, 447 patients were included in 48 academic centres in six countries; 120 in the EWOC-1 trial and 327 in the EWOC-1 registry. Median follow-up was 19·7 (95% CI 8·5-29·7) months for the total cohort; missing values were low (<2%). According to the maximum likelihood analysis, the hazard ratio (HR) of death in V1 was 1·8 (95% CI 1·1-3·1, p=0·029) for those with a GVS of 1; 2·4 (1·4-4·0, p=0·0009) with a GVS of 2; 4·1 (2·5-7·0, p<0·0001) for a GVS of 3; 5·5 (3·3-9·3, p<0·0001) for a GVS of 4; and 9·1 (4·7-17·5, p<0·0001) for a GVS of 5 compared with a score of 0. Whatever the validation cohort, GVS of 3 or more significantly segregated two groups with different overall survival: V1 (median 13·2 [95% CI: 10·8-18·7] vs 40·8 [32·0-45·6] months; HR 2·8 [95% CI 2·2-3·7]; p<0·0001); V2 (11·9 [95% CI 8·8-18·1] vs 40·8 [32·0-45·6] months, HR 3·5 [2·5-4·9]; p<0·0001); and V3 (18·1 [95% CI 15·8-31·8] vs 43·0 [40·6-49·7] months, HR 2·6 [1·9 to 3·7]; p<0·0001).

INTERPRETATION: The GVS has high prognostic performance for overall survival in patients with advanced ovarian cancer, independently of geographic and historic effect (V1), as well as treatment patterns (V3), validated in an international population. Even though the GVS is time consuming it will allow the stratification of populations for clinical research and might permit the orientation of the geriatric intervention to specific domains.

FUNDING: French National Cancer Institute.

TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

Для цитирования: Falandry Claire, Pommeret Fanny, Gladieff Laurence, Tinquaut Fabien, Lorusso Domenica, Mouret-Reynier Marie-Ange, D'Hondt Véronique, Mollon-Grange Delphine, Floquet Anne, Abadie-Lacourtoisie Sophie, Brachet Pierre-Emmanuel, Stefani Laetitia, Rousseau Frédérique, Frenel Jean-Sébastien, Del Piano Francesco, Komulainen Marja, Warkus Thomas, Trédan Olivier, Pujade-Lauraine Eric, Freyer Gilles. Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study.. The lancet. Healthy longevity. 2022. DOI: 10.1016/s2666-7568(22)00002-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.